騰盛博藥-B(02137.HK)香港公開發售獲292倍認購 上限定價每股22.25港元
格隆匯7月12日丨騰盛博藥-B(02137.HK)發佈公吿,公司全球發售1.1158億股股份,其中香港發售股份5579萬股,國際發售股份5579萬股,另有15%超額配股權;發售價釐定為每股發售股份22.25港元,每手買賣單位500股;摩根士丹利及瑞銀為聯席保薦人,預期股份將於2021年7月13日於聯交所主板掛牌上市。
國際發售項下初步提呈發售的發售股份已獲大幅超額認購,相當於國際發售項下初步可供認購發售股份總數的約12倍。香港公開發售項下初步提呈發售的香港發售股份獲大量超額認購。合共接獲246,540份有效申請,認購合共32.59億股香港發售股份,相當於香港公開發售項下初步可供認購香港發售股份總數約292倍。
基於發售價每股發售股份22.25港元,根據基石投資協議,基石投資者已認購合共5302.75萬股發售股份,相當於全球發售完成後公司已發行股本的約7.51%及全球發售項下發售股份數目的47.52%,兩種情況均假設超額配股權未獲行使。
基於發售價每股發售股份22.25港元,公司將收取的全球發售所得款項淨額估計約為23.338億港元(假設超額配股權未獲行使)。公司擬將有關所得款項淨額約55%劃撥至HBV功能性治癒項目的進一步發展;所得款項淨額的約15%將劃撥至HIV項目,用於為BRII-778和BRII-732正在進行及計劃的臨牀試驗及登記備案准備提供資金;約15%將劃撥至MDR/XDR革蘭氏陰性菌感染項目;約5%將用於為BRII296正在進行及計劃的臨牀試驗及登記備案准備提供資金;及約10%將劃撥至公司的早期階段管線、業務發展計劃、營運資金及一般企業用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.